DK1283735T4 - Fremgangsmåde til forbedring signalering af øceller ved diabetes mellitus og til forebyggelse deraf - Google Patents

Fremgangsmåde til forbedring signalering af øceller ved diabetes mellitus og til forebyggelse deraf

Info

Publication number: DK1283735T4
Authority: DK; Denmark
Prior art keywords: cells; insulin producing; pancreatic; prevention; diabetes mellitus
Prior art date: 2000-03-31

Application number

DK01927848.0T

Other languages

English (en)

Other versions

DK1283735T3 (da

Inventor

Konrad Glund

Hans-Ulrich Demuth

Original Assignee

Royalty Pharma Collection Trust

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-03-31

Filing date

2001-04-02

Publication date

2013-02-04

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22716142&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1283735(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2001-04-02 Application filed by Royalty Pharma Collection Trust filed Critical Royalty Pharma Collection Trust

2009-04-06 Publication of DK1283735T3 publication Critical patent/DK1283735T3/da

2013-02-04 Application granted granted Critical

2013-02-04 Publication of DK1283735T4 publication Critical patent/DK1283735T4/da

Links

238000000034 method Methods 0.000 title abstract 2
230000005754 cellular signaling Effects 0.000 title 1
206010012601 diabetes mellitus Diseases 0.000 title 1
210000004153 islets of langerhan Anatomy 0.000 title 1
230000002265 prevention Effects 0.000 title 1
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 6
102000004877 Insulin Human genes 0.000 abstract 3
108090001061 Insulin Proteins 0.000 abstract 3
229940125396 insulin Drugs 0.000 abstract 3
102100025101 GATA-type zinc finger protein 1 Human genes 0.000 abstract 2
101710198884 GATA-type zinc finger protein 1 Proteins 0.000 abstract 2
DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 abstract 2
230000004069 differentiation Effects 0.000 abstract 2
241000124008 Mammalia Species 0.000 abstract 1
210000004027 cell Anatomy 0.000 abstract 1
210000002919 epithelial cell Anatomy 0.000 abstract 1
230000002641 glycemic effect Effects 0.000 abstract 1
239000003112 inhibitor Substances 0.000 abstract 1
238000012423 maintenance Methods 0.000 abstract 1
210000004923 pancreatic tissue Anatomy 0.000 abstract 1
230000004962 physiological condition Effects 0.000 abstract 1
230000008929 regeneration Effects 0.000 abstract 1
238000011069 regeneration method Methods 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Immunology (AREA)
Endocrinology (AREA)
Communicable Diseases (AREA)
Physical Education & Sports Medicine (AREA)
Virology (AREA)
Hematology (AREA)
Oncology (AREA)
Rheumatology (AREA)
Obesity (AREA)
Tropical Medicine & Parasitology (AREA)
Emergency Medicine (AREA)
Pain & Pain Management (AREA)
Transplantation (AREA)
AIDS & HIV (AREA)
Molecular Biology (AREA)
Orthopedic Medicine & Surgery (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Thiazole And Isothizaole Compounds (AREA)
Enzymes And Modification Thereof (AREA)

DK01927848.0T 2000-03-31 2001-04-02 Fremgangsmåde til forbedring signalering af øceller ved diabetes mellitus og til forebyggelse deraf DK1283735T4 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US19406100P	2000-03-31	2000-03-31
PCT/EP2001/003725 WO2001072290A2 (en)	2000-03-31	2001-04-02	Method for the improvement of islet signaling in diabetes mellitus and for its prevention

Publications (2)

Publication Number	Publication Date
DK1283735T3 DK1283735T3 (da)	2009-04-06
DK1283735T4 true DK1283735T4 (da)	2013-02-04

Family

ID=22716142

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK01927848.0T DK1283735T4 (da)	2000-03-31	2001-04-02	Fremgangsmåde til forbedring signalering af øceller ved diabetes mellitus og til forebyggelse deraf
DK08172906.3T DK2055302T3 (da)	2000-03-31	2001-04-02	Fremgangsmåde til forbedring af signalering af øceller ved diabetes mellitus og til forebyggelse deraf

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
DK08172906.3T DK2055302T3 (da)	2000-03-31	2001-04-02	Fremgangsmåde til forbedring af signalering af øceller ved diabetes mellitus og til forebyggelse deraf

Country Status (21)

Country	Link
US (5)	US6500804B2 (da)
EP (3)	EP2266665B1 (da)
JP (1)	JP2003528135A (da)
KR (2)	KR20080067009A (da)
CN (2)	CN101690815A (da)
AT (1)	ATE419036T1 (da)
AU (2)	AU2001254763A1 (da)
BR (1)	BR0109553A (da)
CA (1)	CA2400226C (da)
CY (1)	CY1108872T1 (da)
CZ (1)	CZ20023234A3 (da)
DE (1)	DE60137216D1 (da)
DK (2)	DK1283735T4 (da)
ES (3)	ES2525041T3 (da)
HU (1)	HU229042B1 (da)
IL (1)	IL151368A0 (da)
NO (1)	NO20024643L (da)
PT (3)	PT1283735E (da)
RU (1)	RU2261096C2 (da)
WO (1)	WO2001072290A2 (da)
ZA (1)	ZA200206460B (da)

Families Citing this family (122)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20020006899A1 (en) *	1998-10-06	2002-01-17	Pospisilik Andrew J.	Use of dipeptidyl peptidase IV effectors for lowering blood pressure in mammals
BR9813233A (pt)	1997-09-29	2000-08-22	Point Therapeutics Inc	Estimulação de células hematopoéticas in vitro
DE19823831A1 (de) *	1998-05-28	1999-12-02	Probiodrug Ges Fuer Arzneim	Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
DE19828113A1 (de) *	1998-06-24	2000-01-05	Probiodrug Ges Fuer Arzneim	Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
US6979697B1 (en) *	1998-08-21	2005-12-27	Point Therapeutics, Inc.	Regulation of substrate activity
US20030176357A1 (en) *	1998-10-06	2003-09-18	Pospisilik Andrew J.	Dipeptidyl peptidase IV inhibitors and their uses for lowering blood pressure levels
US6890904B1 (en)	1999-05-25	2005-05-10	Point Therapeutics, Inc.	Anti-tumor agents
DE19940130A1 (de) *	1999-08-24	2001-03-01	Probiodrug Ges Fuer Arzneim	Neue Effektoren der Dipeptidyl Peptidase IV zur topischen Anwendung
US20030040469A1 (en) *	2000-03-08	2003-02-27	Knudsen Liselotte Bjerre	Lowering serum lipids
DK1283735T4 (da) *	2000-03-31	2013-02-04	Royalty Pharma Collection Trust	Fremgangsmåde til forbedring signalering af øceller ved diabetes mellitus og til forebyggelse deraf
ES2309108T3 (es) *	2000-10-27	2008-12-16	Probiodrug Ag	Tratamiento de enfermedades neurologicas y neuropsicologicas.
US20020187926A1 (en) *	2001-03-07	2002-12-12	Knudsen Liselotte Bjerre	Combined use of derivatives of GLP-1 analogs and PPAR ligands
US20030022816A1 (en) *	2001-03-07	2003-01-30	Knudsen Liselotte Bjerre	Combined use of derivatives of GLP-1 analogs and PPAR ligands
US20070293426A1 (en) *	2001-04-02	2007-12-20	Hans-Ulrich Demuth	Methods for improving islet signaling in diabetes mellitus and for its prevention
US6890905B2 (en) *	2001-04-02	2005-05-10	Prosidion Limited	Methods for improving islet signaling in diabetes mellitus and for its prevention
GB0109146D0 (en) *	2001-04-11	2001-05-30	Ferring Bv	Treatment of type 2 diabetes
US7368421B2 (en) *	2001-06-27	2008-05-06	Probiodrug Ag	Use of dipeptidyl peptidase IV inhibitors in the treatment of multiple sclerosis
US20030130199A1 (en) *	2001-06-27	2003-07-10	Von Hoersten Stephan	Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents
EP1406873B1 (en)	2001-06-27	2007-09-26	Smithkline Beecham Corporation	Fluoropyrrolidines as dipeptidyl peptidase inhibitors
EP1492525A2 (en) *	2001-08-16	2005-01-05	Probiodrug AG	Use of inhibitors of proline endopeptidase to modulate inositol (1,4,5) triphosphate concentration dependent on intracellular signal cascades
US6844316B2 (en) *	2001-09-06	2005-01-18	Probiodrug Ag	Inhibitors of dipeptidyl peptidase I
CA2466870A1 (en) *	2001-11-26	2003-06-05	Trustees Of Tufts College	Methods for treating autoimmune disorders, and reagents related thereto
PT1480961E (pt) *	2002-02-28	2007-02-28	Prosidion Ltd	Inibidores de dpiv à base de glutaminilo
US20030232761A1 (en) *	2002-03-28	2003-12-18	Hinke Simon A.	Novel analogues of glucose-dependent insulinotropic polypeptide
US20040023885A1 (en)	2002-06-07	2004-02-05	Brand Stephen J	Compositions and methods for treating diabetes
ATE394118T1 (de) *	2002-08-09	2008-05-15	Prosidion Ltd	Dipeptidyl peptidase iv inhibitoren zur senkung der chronische gewichtszunahme
US7407955B2 (en) *	2002-08-21	2008-08-05	Boehringer Ingelheim Pharma Gmbh & Co., Kg	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
EP1537880A4 (en) *	2002-09-11	2009-07-01	Takeda Pharmaceutical	Sustained release preparation
WO2004031374A2 (en) *	2002-09-18	2004-04-15	Prosidion Ltd.	Secondary binding site of dipeptidyl peptidase iv (dp iv)
US20040058876A1 (en) *	2002-09-18	2004-03-25	Torsten Hoffmann	Secondary binding site of dipeptidyl peptidase IV (DP IV)
EP1569680B1 (en) *	2002-10-22	2009-01-21	Waratah Pharmaceuticals, Inc.	Treatment of diabetes
DE10308352A1 (de)	2003-02-27	2004-09-09	Aventis Pharma Deutschland Gmbh	Arylcycloalkylderivate mit verzweigten Seitenketten, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE10308351A1 (de)	2003-02-27	2004-11-25	Aventis Pharma Deutschland Gmbh	1,3-substituierte Cycloalkylderivate mit sauren, meist heterocyclischen Gruppen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE10308353A1 (de)	2003-02-27	2004-12-02	Aventis Pharma Deutschland Gmbh	Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US7148246B2 (en)	2003-02-27	2006-12-12	Sanofi-Aventis Deutschland Gmbh	Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals
DE10308355A1 (de)	2003-02-27	2004-12-23	Aventis Pharma Deutschland Gmbh	Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
EP1608317B1 (en) *	2003-03-25	2012-09-26	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
WO2004098591A2 (en) *	2003-05-05	2004-11-18	Probiodrug Ag	Inhibitors of glutaminyl cyclase and their use in the treatment of neurological diseases
KR20060009902A (ko) *	2003-05-05	2006-02-01	프로비오드룩 아게	글루타미닐 및 글루타메이트 사이클라제의 이펙터의 용도
EP1625122A1 (en)	2003-05-14	2006-02-15	Takeda San Diego, Inc.	Dipeptidyl peptidase inhibitors
US7790736B2 (en)	2003-08-13	2010-09-07	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
US7678909B1 (en)	2003-08-13	2010-03-16	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
US7169926B1 (en)	2003-08-13	2007-01-30	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
WO2005026148A1 (en)	2003-09-08	2005-03-24	Takeda San Diego, Inc.	Dipeptidyl peptidase inhibitors
WO2005030751A2 (en) *	2003-09-08	2005-04-07	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
AU2004283461B2 (en) *	2003-10-15	2010-02-11	Probiodrug Ag	Use of effectors of glutaminyl and glutamate cyclases
ES2231036B1 (es) *	2003-10-31	2006-07-01	Encofrados J. Alsina, S.A.	Puntal.
US20050171112A1 (en) *	2003-11-03	2005-08-04	Probiodrug Ag	Combinations useful for the treatment of neuronal disorders
US20100099721A1 (en) *	2003-11-03	2010-04-22	Probiodrug Ag	Novel compounds for the treatment of neurological disorders
MXPA06005518A (es)	2003-11-17	2006-08-17	Novartis Ag	Uso de inhibidores de la dipeptidil peptidasa iv.
NZ578743A (en)	2004-01-20	2011-04-29	Novartis Ag	Direct compression formulation and process
US7241787B2 (en) *	2004-01-25	2007-07-10	Sanofi-Aventis Deutschland Gmbh	Substituted N-cycloexylimidazolinones, process for their preparation and their use as medicaments
EP1713780B1 (en)	2004-02-05	2012-01-18	Probiodrug AG	Novel inhibitors of glutaminyl cyclase
US7501426B2 (en)	2004-02-18	2009-03-10	Boehringer Ingelheim International Gmbh	8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
MXPA06009589A (es) *	2004-02-23	2007-03-26	Tufts College	Inhibidores de dipeptidil peptidasa iv par regular el metabolismo de glucosa.
US7732446B1 (en)	2004-03-11	2010-06-08	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
EA013427B1 (ru)	2004-03-15	2010-04-30	Такеда Фармасьютикал Компани Лимитед	Ингибиторы дипептидилпептидазы
DE602004004631D1 (de)	2004-04-01	2007-03-22	Sanofi Aventis Deutschland	Oxadiazolone, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Pharmazeutika
US7687638B2 (en)	2004-06-04	2010-03-30	Takeda San Diego, Inc.	Dipeptidyl peptidase inhibitors
WO2006019965A2 (en)	2004-07-16	2006-02-23	Takeda San Diego, Inc.	Dipeptidyl peptidase inhibitors
AU2005267093B2 (en)	2004-07-23	2009-10-01	Nuada Llc	Peptidase inhibitors
WO2006022428A1 (ja) *	2004-08-26	2006-03-02	Takeda Pharmaceutical Company Limited	糖尿病治療剤
US20060063719A1 (en) *	2004-09-21	2006-03-23	Point Therapeutics, Inc.	Methods for treating diabetes
DE102004054054A1 (de)	2004-11-05	2006-05-11	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
US7872124B2 (en)	2004-12-21	2011-01-18	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
BRPI0608469A2 (pt)	2005-04-22	2010-01-05	Alantos Pharmaceuticals Holding Inc	inibidores de dipeptidil peptidase-iv
DE102005026762A1 (de)	2005-06-09	2006-12-21	Sanofi-Aventis Deutschland Gmbh	Azolopyridin-2-on-derivate als Inhibitoren von Lipasen und Phospholipasen
MY152185A (en)	2005-06-10	2014-08-29	Novartis Ag	Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation
DE102005035891A1 (de)	2005-07-30	2007-02-08	Boehringer Ingelheim Pharma Gmbh & Co. Kg	8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
US20090202497A1 (en) *	2005-08-23	2009-08-13	The General Hospital Corporation	Use of glp-1, glp-1 derivatives or glp-1 fragments for skin regeneration, stimulation of hair growth, or treatment of diabetes
JP5027137B2 (ja)	2005-09-14	2012-09-19	武田薬品工業株式会社	ジペプチジルペプチダーゼ阻害剤の投与
CN102908351B (zh) *	2005-09-14	2014-07-23	武田药品工业株式会社	用于治疗糖尿病的二肽基肽酶抑制剂
US20070060529A1 (en) *	2005-09-14	2007-03-15	Christopher Ronald J	Administration of dipeptidyl peptidase inhibitors
TW200745080A (en) *	2005-09-16	2007-12-16	Takeda Pharmaceuticals Co	Polymorphs of tartrate salt of 2-[2-(3-(R)-amino-piperidin-1-yl)-5-fluoro-6-oxo-6H-pyrimidin-1-ylmethyl]-benzonitrile and methods of use therefor
TW200745079A (en) *	2005-09-16	2007-12-16	Takeda Pharmaceuticals Co	Polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile and methods of use therefor
KR101368988B1 (ko)	2005-09-16	2014-02-28	다케다 야쿠힌 고교 가부시키가이샤	디펩티딜 펩티다제 억제제
CA2623826A1 (en) *	2005-09-30	2007-04-12	Novartis Ag	Dpp iv inhibitor for use in the treatment of autoimmune diseases and graft rejection
CN101365476A (zh) *	2005-10-07	2009-02-11	瓦拉塔药品公司	Dpp-iv抑制剂和胃泌素化合物的联合使用
AT502717A1 (de) *	2005-11-09	2007-05-15	Omnica Gmbh	Pharmazeutische verwendung einer verbindung
GB0526291D0 (en)	2005-12-23	2006-02-01	Prosidion Ltd	Therapeutic method
WO2007112347A1 (en)	2006-03-28	2007-10-04	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
WO2007112368A1 (en) *	2006-03-28	2007-10-04	Takeda Pharmaceutical Company Limited	Preparation of (r)-3-aminopiperidine dihydrochloride
CN109503584A (zh)	2006-05-04	2019-03-22	勃林格殷格翰国际有限公司	多晶型
EP1852108A1 (en)	2006-05-04	2007-11-07	Boehringer Ingelheim Pharma GmbH & Co.KG	DPP IV inhibitor formulations
PE20110235A1 (es)	2006-05-04	2011-04-14	Boehringer Ingelheim Int	Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
US8324383B2 (en)	2006-09-13	2012-12-04	Takeda Pharmaceutical Company Limited	Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
CN101616673A (zh) *	2006-09-13	2009-12-30	武田药品工业株式会社	2-[6-(3-氨基-哌啶-1-基)-3-甲基-2,4-二氧代-3,4-二氢-2h-嘧啶-1-基甲基]-4-氟-苄腈的用途
TW200838536A (en)	2006-11-29	2008-10-01	Takeda Pharmaceutical	Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
US8093236B2 (en)	2007-03-13	2012-01-10	Takeda Pharmaceuticals Company Limited	Weekly administration of dipeptidyl peptidase inhibitors
US20080293644A1 (en) *	2007-04-27	2008-11-27	Thomas Eidenberger	Guava extract
MX2010001821A (es) *	2007-08-17	2010-03-10	Boehringer Ingelheim Int	Derivados de purina para uso en el tratamiento de enfermedades relacionadas con fap.
PE20140960A1 (es)	2008-04-03	2014-08-15	Boehringer Ingelheim Int	Formulaciones que comprenden un inhibidor de dpp4
PE20100156A1 (es) *	2008-06-03	2010-02-23	Boehringer Ingelheim Int	Tratamiento de nafld
KR20190016601A (ko)	2008-08-06	2019-02-18	베링거 인겔하임 인터내셔날 게엠베하	메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
UY32030A (es)	2008-08-06	2010-03-26	Boehringer Ingelheim Int	"tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
ES2764251T3 (es) *	2008-08-15	2020-06-02	Boehringer Ingelheim Int	Inhibidores de DPP-4 para uso en el tratamiento de curación de heridas en pacientes diabéticos
WO2010029089A2 (en)	2008-09-10	2010-03-18	Boehringer Ingelheim International Gmbh	Combination therapy for the treatment of diabetes and related conditions
US20200155558A1 (en)	2018-11-20	2020-05-21	Boehringer Ingelheim International Gmbh	Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
US9144205B2 (en)	2008-10-17	2015-09-29	Alchem Environmental Ip Llc	Hydroponics applications and ancillary modifications to a polyphasic pressurized homogenizer
US8241410B1 (en)	2008-10-17	2012-08-14	Alchem Environmental LLC	Ancillary embodiments and modifications to a polyphasic pressurized homogenizer
US9757683B1 (en)	2008-10-17	2017-09-12	Alchem Environmental Ip Llc	Polyphasic pressurized homogenizer (PPH) and methods for methane purification
EP2382216A1 (en)	2008-12-23	2011-11-02	Boehringer Ingelheim International GmbH	Salt forms of organic compound
TW201036975A (en)	2009-01-07	2010-10-16	Boehringer Ingelheim Int	Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
WO2010108144A1 (en) *	2009-03-19	2010-09-23	Georgia Tech Research Corporation	Systems and methods for improved wireless interface aggregation
NZ599298A (en)	2009-11-27	2014-11-28	Boehringer Ingelheim Int	Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
KR101927068B1 (ko)	2010-05-05	2018-12-10	베링거 인겔하임 인터내셔날 게엠베하	체중 감소 치료에 후속하는 dpp-4 억제제에 의한 순차적 병용 요법
CN106975074A (zh)	2010-06-24	2017-07-25	勃林格殷格翰国际有限公司	糖尿病治疗
US9034883B2 (en)	2010-11-15	2015-05-19	Boehringer Ingelheim International Gmbh	Vasoprotective and cardioprotective antidiabetic therapy
CN102807568B (zh) *	2011-05-31	2015-11-25	正大天晴药业集团股份有限公司	噻二唑衍生物类dpp-iv抑制剂
ES2713566T3 (es)	2011-07-15	2019-05-22	Boehringer Ingelheim Int	Derivado de quinazolina dimérico sustituido, su preparación y su uso en composiciones farmacéuticas para el tratamiento de la diabetes de tipo I y II
US9555001B2 (en)	2012-03-07	2017-01-31	Boehringer Ingelheim International Gmbh	Pharmaceutical composition and uses thereof
EP3685839A1 (en)	2012-05-14	2020-07-29	Boehringer Ingelheim International GmbH	Linagliptin for use in the treatment of albuminuria and kidney related diseases
EP4151218A1 (en)	2012-05-14	2023-03-22	Boehringer Ingelheim International GmbH	Linagliptin, a xanthine derivative as dpp-4 inhibitor, for use in the treatment of sirs and/or sepsis
WO2013174767A1 (en)	2012-05-24	2013-11-28	Boehringer Ingelheim International Gmbh	A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
US9526728B2 (en)	2014-02-28	2016-12-27	Boehringer Ingelheim International Gmbh	Medical use of a DPP-4 inhibitor
CN105315301B (zh) *	2014-08-05	2018-04-03	连云港润众制药有限公司	噻二唑类dpp‑ⅳ抑制剂的枸橼酸盐
KR20180006881A (ko)	2015-03-09	2018-01-19	인테크린 테라퓨틱스, 아이엔씨.	비알코올성 지방간 질환 및/또는 지방이영양증의 치료 방법
EP4233840A3 (en)	2016-06-10	2023-10-18	Boehringer Ingelheim International GmbH	Combinations of linagliptin and metformin
CN106620704A (zh) *	2016-11-04	2017-05-10	广州赛莱拉干细胞科技股份有限公司	一种治疗糖尿病的制剂及其制备方法和应用
WO2018162722A1 (en)	2017-03-09	2018-09-13	Deutsches Institut Für Ernährungsforschung Potsdam-Rehbrücke	Dpp-4 inhibitors for use in treating bone fractures
WO2018187350A1 (en)	2017-04-03	2018-10-11	Coherus Biosciences Inc.	PPARγ AGONIST FOR TREATMENT OF PROGRESSIVE SUPRANUCLEAR PALSY
CN112386217A (zh) *	2019-08-14	2021-02-23	关永晖	一种膀胱镜注射针

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2961377A (en)	1957-08-05	1960-11-22	Us Vitamin Pharm Corp	Oral anti-diabetic compositions and methods
US3174901A (en) *	1963-01-31	1965-03-23	Jan Marcel Didier Aron Samuel	Process for the oral treatment of diabetes
US3879541A (en) *	1970-03-03	1975-04-22	Bayer Ag	Antihyperglycemic methods and compositions
DE2009743A1 (de)	1970-03-03	1971-09-16	Farbenfabriken Bayer Ag, 5090 Leverkusen	Substituierte Biguanide mit antihyperglykämischer Wirkung
US3960949A (en)	1971-04-02	1976-06-01	Schering Aktiengesellschaft	1,2-Biguanides
CH602612A5 (da) *	1974-10-11	1978-07-31	Hoffmann La Roche
US4935493A (en)	1987-10-06	1990-06-19	E. I. Du Pont De Nemours And Company	Protease inhibitors
US5433955A (en)	1989-01-23	1995-07-18	Akzo N.V.	Site specific in vivo activation of therapeutic drugs
US5462928A (en) *	1990-04-14	1995-10-31	New England Medical Center Hospitals, Inc.	Inhibitors of dipeptidyl-aminopeptidase type IV
JPH04334357A (ja)	1991-05-02	1992-11-20	Fujirebio Inc	酵素阻害作用を有するアシル誘導体
EP0610317B1 (en)	1991-10-22	2001-01-31	New England Medical Center Hospitals, Inc.	Inhibitors of dipeptidyl-aminopeptidase type iv
DK36392D0 (da) *	1992-03-19	1992-03-19	Novo Nordisk As	Anvendelse af kemisk forbindelse
IL106998A0 (en)	1992-09-17	1993-12-28	Univ Florida	Brain-enhanced delivery of neuroactive peptides by sequential metabolism
FR2696740B1 (fr)	1992-10-13	1994-12-30	Dospharma Sa	Dérivés prodrogués de la diméthylbiguanide et applications comme médicaments.
WO1995011689A1 (en)	1993-10-29	1995-05-04	Trustees Of Tufts College	Use of inhibitors of dipeptidyl-aminopeptidase to block entry of hiv into cells
IL111785A0 (en)	1993-12-03	1995-01-24	Ferring Bv	Dp-iv inhibitors and pharmaceutical compositions containing them
US5705483A (en) *	1993-12-09	1998-01-06	Eli Lilly And Company	Glucagon-like insulinotropic peptides, compositions and methods
US5543396A (en)	1994-04-28	1996-08-06	Georgia Tech Research Corp.	Proline phosphonate derivatives
US5512549A (en)	1994-10-18	1996-04-30	Eli Lilly And Company	Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
US5614379A (en)	1995-04-26	1997-03-25	Eli Lilly And Company	Process for preparing anti-obesity protein
DE122010000020I1 (de) *	1996-04-25	2010-07-08	Prosidion Ltd	Verfahren zur Senkung des Blutglukosespiegels in Säugern
EP0914123A4 (en)	1996-05-29	2000-10-11	Prototek Inc	THALIDOMIDE PRODUCTS AND METHODS OF USING SAID PRODUCTS AS T CELL MODIFIERS
US6006753A (en)	1996-08-30	1999-12-28	Eli Lilly And Company	Use of GLP-1 or analogs to abolish catabolic changes after surgery
US5827898A (en) *	1996-10-07	1998-10-27	Shaman Pharmaceuticals, Inc.	Use of bisphenolic compounds to treat type II diabetes
US6011155A (en) *	1996-11-07	2000-01-04	Novartis Ag	N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
TW492957B (en)	1996-11-07	2002-07-01	Novartis Ag	N-substituted 2-cyanopyrrolidnes
AR016751A1 (es)	1996-11-22	2001-08-01	Athena Neurosciences Inc	Metodo para inhibir la liberacion del peptido beta-amiloide en una celula, composicion farmaceutica y compuestos utiles en dicho metodo
US6001155A (en)	1997-03-17	1999-12-14	Pease; John R.	Polyphasic pressurized homogenizer
EP2823812A1 (en)	1998-02-02	2015-01-14	Trustees Of Tufts College	Dipeptidylpeptidase IV inhibitors for use in the treatment of Type II diabetes
JP2002506075A (ja)	1998-03-09	2002-02-26	フォンダテッヒ・ベネルクス・ナムローゼ・フェンノートシャップ	セリンペプチダーゼ調節剤
DE19823831A1 (de) †	1998-05-28	1999-12-02	Probiodrug Ges Fuer Arzneim	Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
DE19828113A1 (de)	1998-06-24	2000-01-05	Probiodrug Ges Fuer Arzneim	Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
DE19828114A1 (de)	1998-06-24	2000-01-27	Probiodrug Ges Fuer Arzneim	Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV
EP1092046A4 (en)	1998-07-02	2003-02-19	Invitro Diagnostics Inc	METHODS, COMPOSITIONS AND DEVICE FOR MANUFACTURING NUCLEIC ACIDS HAVING SELECTIVE AFFINITY FOR A TARGET MOLECULE
EP1100530B1 (en)	1998-07-31	2003-10-08	Novo Nordisk A/S	In-vitro stimulation of beta cell proliferation
DE19834591A1 (de) *	1998-07-31	2000-02-03	Probiodrug Ges Fuer Arzneim	Verfahren zur Steigerung des Blutglukosespiegels in Säugern
WO2000053171A1 (en)	1999-03-05	2000-09-14	Molteni L. E C. Dei Fratelli Alitti Societa' Di Esercizio S.P.A.	Use of metformin in the preparation of pharmaceutical compositions capable of inhibiting the enzyme dipeptidyl peptidase iv
US6172081B1 (en) *	1999-06-24	2001-01-09	Novartis Ag	Tetrahydroisoquinoline 3-carboxamide derivatives
US6110949A (en) *	1999-06-24	2000-08-29	Novartis Ag	N-(substituted glycyl)-4-cyanothiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
US6107317A (en) *	1999-06-24	2000-08-22	Novartis Ag	N-(substituted glycyl)-thiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
JP2003523396A (ja)	2000-02-25	2003-08-05	ノボノルディスクアクティーゼルスカブ	ベータ細胞変性の抑制
US7064145B2 (en) *	2000-02-25	2006-06-20	Novo Nordisk A/S	Inhibition of beta cell degeneration
DK1283735T4 (da) *	2000-03-31	2013-02-04	Royalty Pharma Collection Trust	Fremgangsmåde til forbedring signalering af øceller ved diabetes mellitus og til forebyggelse deraf
US6890905B2 (en) *	2001-04-02	2005-05-10	Prosidion Limited	Methods for improving islet signaling in diabetes mellitus and for its prevention

2001
- 2001-04-02 DK DK01927848.0T patent/DK1283735T4/da active
- 2001-04-02 PT PT01927848T patent/PT1283735E/pt unknown
- 2001-04-02 ES ES08172906.3T patent/ES2525041T3/es not_active Expired - Lifetime
- 2001-04-02 CN CN200910208114A patent/CN101690815A/zh active Pending
- 2001-04-02 IL IL15136801A patent/IL151368A0/xx active IP Right Grant
- 2001-04-02 ES ES01927848T patent/ES2320630T5/es not_active Expired - Lifetime
- 2001-04-02 US US09/824,622 patent/US6500804B2/en not_active Expired - Fee Related
- 2001-04-02 KR KR1020087014806A patent/KR20080067009A/ko not_active Ceased
- 2001-04-02 CA CA002400226A patent/CA2400226C/en not_active Expired - Lifetime
- 2001-04-02 DE DE60137216T patent/DE60137216D1/de not_active Expired - Lifetime
- 2001-04-02 EP EP10179515.1A patent/EP2266665B1/en not_active Expired - Lifetime
- 2001-04-02 AU AU2001254763A patent/AU2001254763A1/en not_active Abandoned
- 2001-04-02 JP JP2001570251A patent/JP2003528135A/ja active Pending
- 2001-04-02 CZ CZ20023234A patent/CZ20023234A3/cs unknown
- 2001-04-02 DK DK08172906.3T patent/DK2055302T3/da active
- 2001-04-02 EP EP08172906.3A patent/EP2055302B1/en not_active Expired - Lifetime
- 2001-04-02 CN CN01807402A patent/CN1420797A/zh active Pending
- 2001-04-02 HU HU0204459A patent/HU229042B1/hu unknown
- 2001-04-02 KR KR1020027013054A patent/KR20030019337A/ko not_active Ceased
- 2001-04-02 PT PT81729063T patent/PT2055302E/pt unknown
- 2001-04-02 AT AT01927848T patent/ATE419036T1/de active
- 2001-04-02 RU RU2002129014/14A patent/RU2261096C2/ru active
- 2001-04-02 EP EP01927848A patent/EP1283735B2/en not_active Expired - Lifetime
- 2001-04-02 PT PT101795151T patent/PT2266665T/pt unknown
- 2001-04-02 BR BR0109553-6A patent/BR0109553A/pt not_active Application Discontinuation
- 2001-04-02 ES ES10179515.1T patent/ES2582376T3/es not_active Expired - Lifetime
- 2001-04-02 WO PCT/EP2001/003725 patent/WO2001072290A2/en not_active Ceased
2002
- 2002-07-16 US US10/196,038 patent/US20020198242A1/en not_active Abandoned
- 2002-07-22 US US10/200,870 patent/US20030008905A1/en not_active Abandoned
- 2002-08-13 ZA ZA200206460A patent/ZA200206460B/en unknown
- 2002-09-27 NO NO20024643A patent/NO20024643L/no unknown
2003
- 2003-10-01 US US10/676,832 patent/US20050222221A1/en not_active Abandoned
2004
- 2004-08-02 US US10/910,176 patent/US20050014703A1/en not_active Abandoned
2006
- 2006-06-01 AU AU2006202344A patent/AU2006202344B2/en not_active Expired
2009
- 2009-03-12 CY CY20091100280T patent/CY1108872T1/el unknown

Also Published As

Publication number	Publication date
HK1051007A1 (en)	2003-07-18
NO20024643L (no)	2002-11-05
ES2320630T5 (es)	2013-03-12
PT1283735E (pt)	2009-03-19
NO20024643D0 (no)	2002-09-27
PT2266665T (pt)	2016-07-07
EP2055302A1 (en)	2009-05-06
ES2525041T3 (es)	2014-12-16
KR20080067009A (ko)	2008-07-17
DK2055302T3 (da)	2014-10-27
EP2266665A1 (en)	2010-12-29
EP2266665B1 (en)	2016-05-11
BR0109553A (pt)	2003-06-03
DK1283735T3 (da)	2009-04-06
JP2003528135A (ja)	2003-09-24
CZ20023234A3 (cs)	2003-01-15
HUP0204459A2 (en)	2003-05-28
IL151368A0 (en)	2003-04-10
ATE419036T1 (de)	2009-01-15
RU2261096C2 (ru)	2005-09-27
EP1283735B2 (en)	2012-10-24
WO2001072290A2 (en)	2001-10-04
US20020198242A1 (en)	2002-12-26
CN1420797A (zh)	2003-05-28
US20050014703A1 (en)	2005-01-20
AU2006202344B2 (en)	2009-01-08
CA2400226A1 (en)	2001-10-04
AU2001254763A1 (en)	2001-10-08
WO2001072290A3 (en)	2002-03-14
DE60137216D1 (de)	2009-02-12
HU229042B1 (en)	2013-07-29
ES2320630T3 (es)	2009-05-27
ZA200206460B (en)	2003-08-13
US20050222221A1 (en)	2005-10-06
US20010051646A1 (en)	2001-12-13
ES2582376T3 (es)	2016-09-12
US20030008905A1 (en)	2003-01-09
KR20030019337A (ko)	2003-03-06
AU2006202344A1 (en)	2006-06-22
PT2055302E (pt)	2014-12-03
EP1283735B1 (en)	2008-12-31
EP2055302B1 (en)	2014-09-10
HUP0204459A3 (en)	2006-01-30
HK1130015A1 (en)	2009-12-18
CA2400226C (en)	2007-01-02
CN101690815A (zh)	2010-04-07
US6500804B2 (en)	2002-12-31
CY1108872T1 (el)	2014-07-02
EP1283735A2 (en)	2003-02-19

Publication	Publication Date	Title
DK1283735T4 (da)	2013-02-04	Fremgangsmåde til forbedring signalering af øceller ved diabetes mellitus og til forebyggelse deraf
AP2002002703A0 (en)	2002-12-31	Combinations of depeptidyl peptidase IV inhibitors and other antidiabetic agents for the treatment of diadetes mellitus.
GB0001449D0 (en)	2000-03-08	Compositions
CY1108769T1 (el)	2014-04-09	Αναστολεις της διπεπτιδυλικης πεπτιδασης iv για μειωση του ρυθμου της χρονιας αυξησης βαρους
WO2003099281A3 (en)	2004-04-01	Administration of a partial fatty acid inhibitor such as ranolazine for the treatment of diabetes
NO20083276L (no)	2000-02-17	Behandling av diabetes med tiazolidindion og sulfonylurea
WO2005060960A3 (en)	2005-11-17	Use of histamine to treat bone disease
US20140154229A1 (en)	2014-06-05	Proteolytic extract from bromelain for the treatment of connective tissue disorders
BG104062A (en)	2000-11-30	Treatment of diabetes with thiazolidindion, stimulant of insulin secretion and alpha-glucosidase inhibitor
AP9901720A0 (en)	1999-12-31	Treatment of diabetes with thiazolidinedione and alpha-glucosidase inhibitors.
AU1908601A (en)	2001-06-04	Method and composition for the treatment of adenoviral ocular infections
CY1117624T1 (el)	2017-04-26	Μεθοδος για τη βελτιωση της σηματοδοτησης νησιδιων στον σακχαρωδη διαβητη και την προληψη
AU2003288793A1 (en)	2004-07-09	Pharmaceutical compound containing silymarin and carbopol®, production method thereof and use of same as a regenerator of tissue and pancreatic cells with endogenous secretion damaged by diabetes mellitus
CO5150158A1 (es)	2002-04-29	Tratamiento antidiabetico novedoso
BRPI0408984A (pt)	2006-03-28	método para tratar uma condição de doença mediada por células neutrofìlicas em um paciente, e, uso de um composto de ligação de histamina
WO2006123178A3 (en)	2007-05-10	Methods and compositions for the treatment of viral diseases
ECSP982541A (es)	1999-02-11	Nuevo metodo de tratamiento ii
ECSP982592A (es)	1999-02-22	Nuevo metodo de tratamiento v
TR200000958T2 (tr)	2000-08-21	Hiperglisemi tedavisinde tiazolidinedion kullanımı.
WO2007057897A3 (en)	2009-02-12	Pharmaceutical composition and method for regulating abnormal cellular proliferation